Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) has reported a significant transaction involving its Chief Technical Officer, Joseph Shulman. On March 19, 2024, Shulman sold 15,515 shares of the company\'s common stock, accruing over $608,000 from the sale. The shares were sold at prices ranging from $39.06 to $39.22, with a weighted average price of $39.22 per share....
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CEO David P. Meeker has sold a portion of his stock in the company, according to a recent filing with the Securities and Exchange Commission. The transaction, which took place on March 19, 2024, involved the sale of 45,494 shares at a weighted average price of $39.22, resulting in a total...
Investors following Arthur J. Gallagher & Co. (NYSE:AJG) might be interested in the recent transactions made by company Vice President Joel D. Cavaness. According to the latest SEC filings, Cavaness has sold shares worth over $308,000. The transactions, which took place on March 18, 2024, involved the sale of 1,207 shares at an average price...
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Chief Financial Officer Hunter C. Smith has sold a total of 15,515 shares of common stock, with the transactions valued at over $600,000. The sales took place on March 19, 2024, and were executed at a weighted average price of $39.22 per share. The price range for these transactions was between...
In a recent transaction on March 15, Ryan D. Werner, the Senior Vice President and Chief Accounting Officer of Riot Platforms, Inc. (NASDAQ:RIOT), sold 35,000 shares of the company\'s common stock. The shares were disposed of at prices ranging from $11.15 to $11.1602, with the total value of the sale amounting to approximately $390,250. The...
Executives from OrbiMed, a leading investment firm in the healthcare sector, have recently made significant purchases of derivative securities from BiomX Inc. (NYSE:PHGE), a company specializing in biological products. This move indicates a bolstered interest in the biotech firm\'s future potential. The transactions, which took place on March 15, 2024, involved OrbiMed Israel BioFund GP...
By Max A. Cherney, Stephen Nellis and Medha Singh SAN JOSE, California (Reuters) -Nvidia\'s stock climbed on Tuesday after the heavyweight chipmaker said its new flagship AI processor is expected to ship later this year and CEO Jensen Huang said he is chasing a data center market potentially greater than $250 billion. Nvidia (NASDAQ:NVDA)\'s stock...
In a recent transaction, David W. Ruttenberg, a director at Accel Entertainment, Inc. (NYSE:ACEL), sold a total of 25,000 shares of the company\'s stock, garnering over $280,000. The shares were sold at prices ranging from $11.343 to $11.3441, as reported in the company\'s latest SEC filing. The transactions took place on March 15, 2024, and...
In a recent transaction, Karl Peterson, a director at Accel Entertainment, Inc. (NYSE:ACEL), sold 10,000 shares of the company\'s stock at a price of $11.47 per share, totaling $114,700. This sale took place on March 19, 2024, and was disclosed in a filing with the Securities and Exchange Commission. Accel Entertainment, which operates in the...
In a recent transaction, Brett G. Taylor, a director at Kimbell Royalty Partners, LP (NYSE:KRP), sold 27,163 shares of the company\'s stock. The shares were sold at a weighted average price of $15.51, amounting to a total value of approximately $421,298. According to the details provided, the sale took place on March 19, 2024, and...